Sibylla Biotech
Sibylla Biotech is a preclinical stage company focused on developing small molecule degraders using a novel mechanism of action to create new therapeutics for unmet medical needs. Their platform leverages computer simulations and AI methods to discover and develop compounds that induce the degradation of target proteins by interfering with their folding pathways. The company aims to address various therapeutic areas through its innovative PPI-FIT technology, which is applicable across multiple diseases. With a strong foundation in academic excellence and a collaborative environment, Sibylla is positioned to make significant advancements in drug discovery and development.
Sibylla Biotech
Sibylla Biotech is a preclinical stage company focused on developing small molecule degraders using a novel mechanism of action to create new therapeutics for unmet medical needs. Their platform leverages computer simulations and AI methods to discover and develop compounds that induce the degradation of target proteins by interfering with their folding pathways. The company aims to address various therapeutic areas through its innovative PPI-FIT technology, which is applicable across multiple diseases. With a strong foundation in academic excellence and a collaborative environment, Sibylla is positioned to make significant advancements in drug discovery and development.